 |
|
|
| |
Tenofovir Alafenamide Pharmacokinetics in Renal Impairment:
Potential for Administration without Dose Adjustment
|
| |
| |
S Ramanathan,1 JM Custodio,1 M Fordyce,1 W Garner,1 M Vimal,1 G Klein,2 PE Pergola,3 A Cheng,1 and BP Kearney1
1Gilead Sciences, Inc., Foster City, CA USA; 2APEX GmbH, Munich, Germany; 3Renal Associates, PA, San Antonio, Texas, USA
|
| |
|
|
|
|
|
